Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | JAK1 | P23458 | 2/20 | 0.47 |
| ▸ | TYK2 | P29597 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | F13A1 | P00488 | 2/20 | 0.44 |
| ▸ | TGM2 | P21980 | 2/20 | 0.44 |
| ▸ | TGM1 | P22735 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6957499 | 0.93 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL6968165 | 0.89 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19LCK | |
| SCHEMBL22869197 | 0.88 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19LCK | |
| SCHEMBL15619766 | 0.85 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL3272711 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19LCK | |
| SCHEMBL1320424 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19LCK | |
| SCHEMBL3277927 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19LCK | |
| SCHEMBL4203474 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19LCK | |
| SCHEMBL17648490 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19JAK2 | |
| SCHEMBL21806874 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| CN-101490041-A | 2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | CN | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
| EP-1060178-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6610707-B1 | Moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases and nerve damage. | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1060178-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999045006-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | SMN1; SMN2 1708/4885NPC1 3699/4885RAB9A 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.